In addition to accessing the drug via specialty distribution, Eli Lilly made the decision to offer physicians and healthcare practices the opportunity to order CYRAMZA through Biologics as an alternative option.
Lilly Oncology vice president Newt Crenshaw said: "We are pleased to engage with Biologics as our exclusive specialty pharmacy partner, providing our customers with an additional option to access CYRAMZA for their patients."
Biologics will provide patient specific support that will ensure continuity of care for the patient and allow for complete visibility into patient outcomes. Each patient will also be assigned a dedicated care team to provide initial drug information and ongoing clinical support as needed.
In addition to providing its high-touch Oncology Pharmacy Services, Biologics’ Patient Access Services team will perform benefits investigation, benefits verification and prior authorization services. The team will also help facilitate copayment or coinsurance assistance offered by the manufacturer or third-party foundations for eligible patients.